The page cannot be found

The page cannot be found

The page you are looking for might have been removed, had its name changed, or is temporarily unavailable.

Please try the following:

  • Make sure that the Web site address displayed in the address bar of your browser is spelled and formatted correctly.
  • If you reached this page by clicking a link, contact the Web site administrator to alert them that the link is incorrectly formatted.
  • Click the Back button to try another link.

HTTP Error 404 - File or directory not found.
Internet Information Services (IIS)


Technical Information (for support personnel)

  • Go to Microsoft Product Support Services and perform a title search for the words HTTP and 404.
  • Open IIS Help, which is accessible in IIS Manager (inetmgr), and search for topics titled Web Site Setup, Common Administrative Tasks, and About Custom Error Messages.

Pharmaceutical Science Department

Hassan Almoazen

Hassan


Craige Wrenn

Wrenn

My interests are mainly concerned with the neuropharmacology and neuroanatomy of learning and memory.  Specifically, we are focusing our efforts on mouse models of Alzheimer's disease and the behavioral functions of the M2 subtype of muscarinic receptor.

Natalie

List of summer students and what they did (each of these students is continuing to work this fall):
Natalie Arter (BSPS).  Natalie is working on developing a mouse model of an Alzheimer's Disease by using a toxin that is selective for the cholinergic neurons of the forebrain. 
Natalie Bainbridge (PharmD).  Natalie is studying the behavioral phenotype of mice which lack the M2 subtype of muscarinic receptor (M2 KO mice).
Stephanie Swain (Pre-Pharmacy).  Stephanie is also studying the behavioral phenotype of mice which lack the M2 subtype of muscarinic receptor (M2 KO mice).

Another student, Lisa Koselke (Pre-Pharm), has joined the lab this fall and is participating in the M2 KO project.


Bob Soltis

The focus of my research is to examine the mechanisms and pathways in the brain that interact to control or influence stress-induced changes in behavior and neuroendocrine and cardiovascular function. The approach taken in these studies is to inject drugs into discrete areas of the brain of conscious rats during normal and stressful conditions. By examining the cardiovascular, neuroendocrine and behavioral changes resulting from pharmacologically modifying neurotransmission in specific regions of the brain, it will be possible to determine the role of specific neurotransmitter systems and central pathways that mediate stress-induced changes. The long term goals of this work are to enhance our understanding of the neural basis for certain cardiovascular disorders and to suggest strategies for drug development and therapy aimed at their treatment or prevention.

Pharmaceutical Science Department-->

Last Modified: 07/02/2010 04:11:12 by content editor